anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Problem Agitate Solution

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 26,550
Current window 22,471-22,500
Pages 885
Rows per page 30
Arc: Problem Agitate Solutionclear collectionreset all
18 30 60

Arc

22,471-22,500 of 26,550

filter-aware
13
Includes a biological diagram illustrating the RAS protein state transition and mutation impact.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
14
The chart shows lower IC50 values for the Q61X mutation group, suggesting higher sensitivity to the drug.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
15
Waterfall plots showing best percentage change from baseline for two distinct patient cohorts.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
16
Includes a Kaplan-Meier survival curve comparing existing standard-of-care options.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
17
The slide uses a 'before-after' visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
18
The slide highlights US FDA Fast Track designation and superior PFS performance.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
19
The chart is a mirrored bar chart (diverging bar chart) showing AE frequency by grade.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
20
The slide uses a 2D grid to map dose combinations against regulatory requirements (Project Optimus).Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
21
The slide outlines two distinct clinical trial programs (SEACRAFT-1 and SEACRAFT-2) with specific stages, patient cohorts, and regulatory endpoints.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
22
The diagram shows the RAS/MAPK signaling pathway with ERAS-007 targeting ERK.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
23
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
24
The chart is a Kaplan-Meier survival curve comparing a control arm to an experimental arm (EC).Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
25
Shows efficacy data for ERAS-007 in combination with Encorafenib and Cetuximab.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
26
Includes waterfall plot and swimmer plot for clinical trial results.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
27
Data cutoff 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
28
The diagram shows the RAS/MAPK/PI3K signaling pathway. ERAS-801 is shown as an EGFR inhibitor.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
29
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM compared to other indications.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
30
The slide uses a biological diagram to illustrate EGFR mutations in GBM.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
31
The slide uses western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority in mouse models.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
32
The chart is a Kaplan-Meier survival plot comparing three treatment groups.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
33
The diagram illustrates a standard 3+3 or similar dose escalation design leading to an MTD and subsequent safety expansion.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
34
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
35
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
36
Features the Lorenz attractor graphic, which is a signature visual for Erasca.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
37
The table uses a heatmap-style color coding where red indicates red ocean opportunities and teal/green indicates blue ocean opportunities.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
38
The slide uses a two-column layout (Preclinical vs Clinical) to position the company's lead asset against competitors.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
07
Uses authority-citation framework to build urgency by aggregating external validation from reputable news and scientific sources.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
15
Focuses on clinical trial strategy and regulatory milestones.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
16
The slide outlines the randomization, treatment arms, timeline, patient population criteria, and primary/secondary endpoints.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
Uses a combination of an additive equation for the value prop and a chevron-based timeline for the life cycle management.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit